PeerVoice Endocrinology & Metabolic Disorders Audio

PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Endocrinology & Metabolic Disorders that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.

62 episodes

15d ago latest

monthly cadence

English language

▶ Play latestRSS feed Website Science Health Fitness Medicine Education

https://c.peervoice.com/podcast/xml/endocrinology_audio.xml

Episodes 63

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices
2d ago · 38:31
For the complete activity, including supporting material, please visit https://www.peervoice.com/CTG860. Presented by Hannele Yki-Järvinen, MD, FRCP and Jeremy Tomlinson, MD, PhD, FRCP. Learning Objectives: Identify individuals who warrant evaluation for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis based on the presence of cardiometabolic risk factors; Apply available non-invasive scoring systems such as the Fibrosis-4 (FIB-4) Index to predict presence of hepatic fibrosis; Use the outcomes of non-invasive tests to guide referral of individuals to specialist care for su
Raj Chovatiya, MD, PhD, MSCI - In Your Hands: A Case-Based Approach to Treating Moderate-to-Severe Chronic Hand Eczema
15d ago · 23:38
For the complete activity, including supporting material, please visit https://www.peervoice.com/MSG860. Presented by Raj Chovatiya, MD, PhD and Melinda Gooderham, MSc, MD, FRCPC. Learning Objectives: Identify the place in the treatment pathway of chronic hand eczema (CHE) for novel topical treatments; Explain criteria that inform clinical decisions on whether CHE is inadequately controlled on topical corticosteroids; Propose individualised evidence-based treatment strategies for patients with moderate-to-severe CHE that is inadequately controlled on topical corticosteroids.
Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health
2mo ago · 1:17:14
For the complete activity, including supporting material, please visit https://www.peervoice.com/VAC860. Presented by Carel le Roux, MBChB, MSc, PhD; Biykem Bozkurt, MD, PhD; Domenica M. Rubino, MD; and Michael Donnelly-Boylen, MS. Learning Objectives: Describe the pathophysiologic relationship between obesity, metabolic dysfunction, and end-organ injury across cardiovascular, renal, and metabolic disease; Evaluate key clinical and psychosocial factors that influence multidisciplinary management decisions for patients with obesity and related cardiovascular-renal-metabolic disease; Apply evide
Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease
2mo ago · 25:41
For the complete activity, including supporting material, please visit https://www.peervoice.com/YWG860. Presented by Hannele Yki-Järvinen, MD, FRCP and Cyrielle Caussy, MD, PhD. Learning Objectives: Recognise the bidirectional relationship between type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH), including the impact of MASH on glycaemic control, insulin resistance, and complications; Explain the rationale for prompt identification and active management of individuals with MASH and fibrosis, based on the increased risk of adverse liver outcomes associated with
Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice
3mo ago · 35:42
For the complete activity, including supporting material, please visit https://www.peervoice.com/FAK860. Presented by Sven Francque, MD, PhD; and José Luis Calleja Panero, MD, PhD. Learning Objectives: Recall the rationale for prompt identification of metabolic dysfunction-associated steatohepatitis (MASH) in gastroenterology patients, including the high prevalence in specific patient groups, the risk of progression, and the availability of novel treatments; Use recommended non-invasive blood- and image-based methods to evaluate for evidence of steatosis and fibrosis among individuals with car
Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes
4mo ago · 1:19:25
For the complete activity, including supporting material, please visit https://www.peervoice.com/ACQ860. Presented by Colin M. Dayan, MA, MBBS, FRCP, PhD; Michael J. Haller, MD; and Olga Kordonouri, MD. Learning Objectives: Explain the clinical rationale and existing evidence for use of immunomodulatory therapies to delay the progression of type 1 diabetes (T1D); Identify practical workflows and protocols that facilitate the potential integration of immunomodulatory infusions into endocrinology practice, including care pathways for T1D; Evaluate patient perspectives and considerations related
Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can
4mo ago · 20:02
For the complete activity, including supporting material, please visit https://www.peervoice.com/PXK860. Presented by Javier Ampuero, MD, PhD and Meena B. Bansal, MD, FAASLD. Learning Objectives: Explain the rationale for prompt identification and active management of individuals with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, based on the increased risk of adverse liver outcomes associated with progression of fibrosis; Evaluate the impact of novel MASH-targeted therapies, such as THR-β agonists, on the underlying pathophysiology and progression of the disease; Ident
Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies
6mo ago · 21:52
For the complete activity, including supporting material, please visit https://www.peervoice.com/XZR860. Presented by Melanie J. Davies, CBE, MBChB, MD, FMedSci and Linong Ji, MD. Learning Objectives: Describe the importance of optimal cost-effective approaches to the pharmacologic management of type 2 diabetes mellitus (T2DM); Evaluate the role of established medications for T2DM for avoiding potential cardiorenal complications in patients with T2DM; Propose practical approaches to address cost and clinical effectiveness for patients with T2DM.
Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management
7mo ago · 29:06
Visit https://www.peervoice.com/URW860 to view the entire programme with slides. After completing “Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management”, participants will be able to: Identify patients with persistent chylomicronemia, including familial chylomicronemia syndrome (FCS), based on clinical presentation and recommended diagnostic criteria; Recall the mechanisms of and evidence for novel treatments for management of FCS; and Apply comprehensive, patient-centered approaches to th
Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities
8mo ago · 9:49
Visit https://www.peervoice.com/NNA860 to view the entire programme with slides. After completing “Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities”, participants will be able to: Evaluate the impact of APOC-III—directed therapies on clinical and patient-centered outcomes in familial chylomicronemia syndrome (FCS); and Differentiate between APOC-III—directed therapies approved for the management of FCS, including their molecular modalities, frequency of administration, contraindications to use, and adverse-event
John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes
8mo ago · 30:19
Visit https://www.peervoice.com/FTR860 to view the entire programme with slides. After completing “John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes”, participants will be able to: Summarize the complications, burden, and unmet needs associated with the diagnosis and management of hypercortisolism; Describe the mechanistic rationale associated with new and emerging therapies in hypercortisolism; Recall safety and efficacy data rela
Stuart C. Gordon, MD - Data-Driven Decision-Making in Primary Biliary Cholangitis: Evaluating the Expanding Evidence Base for PPAR Agonists
9mo ago · 32:03
Visit https://www.peervoice.com/AEX860 to view the entire programme with slides. After completing “Stuart C. Gordon, MD - Data-Driven Decision-Making in Primary Biliary Cholangitis: Evaluating the Expanding Evidence Base for PPAR Agonists”, participants will be able to: Describe key efficacy and safety outcomes observed with use of PPAR agonists in specific subgroups of people with primary biliary cholangitis (PBC), including those with previous exposure to fibrates or obeticholic acid and those with compensated cirrhosis; Evaluate rates of biochemical response and alkaline phosphatase normali
David Jones, OBE, MD, PhD - New Options and Opportunities for Personalised Treatment of Primary Biliary Cholangitis: Have You Updated Your Approach?
9mo ago · 41:03
Visit https://www.peervoice.com/RNT860 to view the entire programme with slides. After completing “David Jones, OBE, MD, PhD - New Options and Opportunities for Personalised Treatment of Primary Biliary Cholangitis: Have You Updated Your Approach?”, participants will be able to: Describe the contemporary approach to pharmacologic treatment of primary biliary cholangitis (PBC); Identify individuals with PBC who may benefit from initiation of second-line treatment options or a transition in second-line treatment approach; and Apply available data to guide the personalisation of second-line treat
Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room
11mo ago · 18:36
Visit https://www.peervoice.com/NUF860 to view the entire programme with slides. After completing “Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room”, participants will be able to: Discuss the impact of delayed and/or misdiagnosis of a rare cause of abdominal pain on patients and healthcare systems; Recognise the clinical features that would increase suspicion of a rare cause of abdominal pain; and Apply appropriate diagnostic algorithms for patients who present to the emergency room with severe abdomina
Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence
1y ago · 9:55
Visit https://www.peervoice.com/STJ860 to view the entire programme with slides. After completing “Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence”, participants will be able to: Improved knowledge of current efficacy data from clinical trials of novel treatments for familial chylomicronemia syndrome (FCS); and Improved knowledge of the safety profiles of emerging treatments for FCS, based on clinical trial outcomes.
Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment
1y ago · 19:27
Visit https://www.peervoice.com/EAW860 to view the entire programme with slides. After completing “Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment”, participants will be able to: Recognise unmet needs and burdens experienced by patients living with inadequately controlled chronic spontaneous urticaria (CSU); Provide appropriate, individualised treatment to patients with CSU whose symptoms are inadequately controlled with second-generation H1-antihistamines; and Assess the clinical significance of clinical tri
Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice
1y ago · 30:17
Visit https://www.peervoice.com/UYE860 to view the entire programme with slides. After completing “Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice”, participants will be able to: Describe the key components involved in maintaining food intake homeostasis and how these influence appetite and eating behaviour in obesity; Appraise the evidence surrounding phenotype-guided approaches to obesity management; Implement practical, culturally competent strategies to overcome barriers to optimal obesity car
Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis
1y ago · 18:48
Visit https://www.peervoice.com/BAN860 to view the entire programme with slides. After completing “Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis”, participants will be able to: Explain the mechanistic rationale for OX40 pathway inhibitors in atopic dermatitis (AD); Describe the benefits and limitations of current disease management strategies in AD; and Use clinical data to evaluate the effects of emerging OX40 inhibitors for patients with AD in the context of current clinical management.
Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges
1y ago · 19:46
Visit https://www.peervoice.com/HAR860 to view the entire programme with slides. After completing “Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges”, participants will be able to: Evaluate epidemiological evidence on the incidence of misclassification of type 1 diabetes in adults as type 2 diabetes; Recognise differential diagnoses of type 1 diabetes in adults; and Identify patients who are receiving treatment for type 2 diabetes who have clinical features
Francesco Lapi, PharmD, PhD - Chronic, Painful, and Often Overlooked: Working Together to Optimise Outcomes in Hidradenitis Suppurativa
1y ago · 28:11
Visit https://www.peervoice.com/CCB860 to view the entire programme with slides. After completing “Francesco Lapi, PharmD, PhD - Chronic, Painful, and Often Overlooked: Working Together to Optimise Outcomes in Hidradenitis Suppurativa”, participants will be able to: Recognise barriers to optimal care faced by patients with hidradenitis suppurativa (HS), including delays in diagnosis and therapeutic area; Recall the results of clinical trials and real-world studies assessing short- and long-term outcomes associated with the use of biologic therapies in the management of HS; and Formulate approp
Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis
1y ago · 28:39
Visit https://www.peervoice.com/WWZ860 to view the entire programme with slides. After completing “Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis”, participants will be able to: Outline the role of patient perspectives of disease burden in making shared decisions about treatment selection in primary biliary cholangitis (PBC); Summarize the clinical data pertaining to current and emerging first- and second-line therapies used in the management of patients with PBC; Utilize guideline recommendations for evaluation of symptoms and
Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations
1y ago · 20:04
Visit https://www.peervoice.com/EBC860 to view the entire programme with slides. After completing “Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations”, participants will be able to: Explain the rationale for timely diagnosis and optimised treatment of people living with primary biliary cholangitis (PBC); Recognise current gaps in the identification and treatment of PBC, including differences based on factors such as gender, race, age, and geography; and Apply e
Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care
1y ago · 36:14
Visit https://www.peervoice.com/CNZ860 to view the entire programme with slides. After completing “Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care”, participants will be able to: Recognise the role, strengths, and limitations of real-world evidence in guiding decision-making related to stroke prevention in patients with atrial fibrillation (AF); Evaluate available real-world data studies related to the use of oral anticoagulants for stroke prevention in AF, including in special p
Gideon Hirschfield, MB BChir, FRCP, PhD - Keeping Pace With the Latest in PBC: Practical Perspectives on What’s New and What’s Next
1y ago · 30:40
Visit https://www.peervoice.com/BYM860 to view the entire programme with slides. After completing “Gideon Hirschfield, MB BChir, FRCP, PhD - Keeping Pace With the Latest in PBC: Practical Perspectives on What’s New and What’s Next”, participants will be able to: Differentiate between available and emerging therapies for the treatment of primary biliary cholangitis (PBC); Evaluate available efficacy and safety data for emerging therapies for the treatment of PBC; and Define key practical steps in the identification of patients who may benefit from additional lines of treatment for PBC.
Olga Kordonouri, MD - Confronting the Silent Progression of Type 1 Diabetes: Rationales and Roadmaps for Early Detection and Proactive Intervention
1y ago · 53:15
Visit https://www.peervoice.com/GTU860 to view the entire programme with slides. After completing “Olga Kordonouri, MD - Confronting the Silent Progression of Type 1 Diabetes: Rationales and Roadmaps for Early Detection and Proactive Intervention”, participants will be able to: Explain the rationale for conducting autoantibody screening for presymptomatic type 1 diabetes (T1D); Identify current recommendations and practical considerations for conducting autoantibody screening for T1D; Use the results of autoantibody screening for T1D to inform education, monitoring, follow-up, and management p

Episodes

Reading the feed…

Also on peervoice.com

More Science shows

Arizona Science

azpm.org

510 episodes · 9d ago

WiTcast

witcastthailand.com

357 episodes · 8d ago

Evrim Ağacı ile Bilime Dair Her Şey!

evrimagaci.org

557 episodes · 8d ago

A Moment of Science

prxu.org

1,000 episodes · 9d ago

Groks Science Radio Show and Podcast

ocf.berkeley.edu

1,000 episodes · 11d ago

Ask the Naked Scientists

thenakedscientists.com

802 episodes · 9d ago

PeerVoice Endocrinology & Metabolic Disorders Audio

Episodes 63

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices

Raj Chovatiya, MD, PhD, MSCI - In Your Hands: A Case-Based Approach to Treating Moderate-to-Severe Chronic Hand Eczema

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management

Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities

John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes

Stuart C. Gordon, MD - Data-Driven Decision-Making in Primary Biliary Cholangitis: Evaluating the Expanding Evidence Base for PPAR Agonists

David Jones, OBE, MD, PhD - New Options and Opportunities for Personalised Treatment of Primary Biliary Cholangitis: Have You Updated Your Approach?

Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment

Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice

Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Francesco Lapi, PharmD, PhD - Chronic, Painful, and Often Overlooked: Working Together to Optimise Outcomes in Hidradenitis Suppurativa

Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis

Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Gideon Hirschfield, MB BChir, FRCP, PhD - Keeping Pace With the Latest in PBC: Practical Perspectives on What’s New and What’s Next

Olga Kordonouri, MD - Confronting the Silent Progression of Type 1 Diabetes: Rationales and Roadmaps for Early Detection and Proactive Intervention

Episodes

Also on peervoice.com

PeerVoice Internal Medicine Video

PeerVoice Internal Medicine Audio

PeerVoice Clinical Pharmacology Video

PeerVoice Oncology & Haematology Video

PeerVoice Clinical Pharmacology Audio

PeerVoice Oncology & Haematology Audio

More Science shows

Arizona Science

WiTcast

Evrim Ağacı ile Bilime Dair Her Şey!

A Moment of Science

Groks Science Radio Show and Podcast

Ask the Naked Scientists

Episodes 63

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices

Raj Chovatiya, MD, PhD, MSCI - In Your Hands: A Case-Based Approach to Treating Moderate-to-Severe Chronic Hand Eczema

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management

Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities

John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes

Stuart C. Gordon, MD - Data-Driven Decision-Making in Primary Biliary Cholangitis: Evaluating the Expanding Evidence Base for PPAR Agonists

David Jones, OBE, MD, PhD - New Options and Opportunities for Personalised Treatment of Primary Biliary Cholangitis: Have You Updated Your Approach?

Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment

Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice

Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Francesco Lapi, PharmD, PhD - Chronic, Painful, and Often Overlooked: Working Together to Optimise Outcomes in Hidradenitis Suppurativa

Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis

Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Gideon Hirschfield, MB BChir, FRCP, PhD - Keeping Pace With the Latest in PBC: Practical Perspectives on What’s New and What’s Next

Olga Kordonouri, MD - Confronting the Silent Progression of Type 1 Diabetes: Rationales and Roadmaps for Early Detection and Proactive Intervention